Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease

Simone Lista, Henrik Zetterberg, Sidney O'Bryant, Kaj Blennow, Harald Hampel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions (Hampel et al., 2010b; Hampel and Lista, 2013), which are detailed in Table 51.1.

Original languageEnglish
Title of host publicationDementia, Fifth Edition
PublisherCRC Press
Pages528-538
Number of pages11
ISBN (Electronic)9781498703116
ISBN (Print)9781498703123
DOIs
StatePublished - 1 Jan 2017

Fingerprint

Cerebrospinal Fluid
Alzheimer Disease
Biomarkers
National Institute on Aging (U.S.)
Biological Phenomena
Pharmacology

Cite this

Lista, S., Zetterberg, H., O'Bryant, S., Blennow, K., & Hampel, H. (2017). Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease. In Dementia, Fifth Edition (pp. 528-538). CRC Press. https://doi.org/10.1201/9781315381572
Lista, Simone ; Zetterberg, Henrik ; O'Bryant, Sidney ; Blennow, Kaj ; Hampel, Harald. / Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease. Dementia, Fifth Edition. CRC Press, 2017. pp. 528-538
@inbook{ee441664af0c4bf38c98c409c0d33a89,
title = "Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease",
abstract = "In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80{\%} (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions (Hampel et al., 2010b; Hampel and Lista, 2013), which are detailed in Table 51.1.",
author = "Simone Lista and Henrik Zetterberg and Sidney O'Bryant and Kaj Blennow and Harald Hampel",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/9781315381572",
language = "English",
isbn = "9781498703123",
pages = "528--538",
booktitle = "Dementia, Fifth Edition",
publisher = "CRC Press",

}

Lista, S, Zetterberg, H, O'Bryant, S, Blennow, K & Hampel, H 2017, Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease. in Dementia, Fifth Edition. CRC Press, pp. 528-538. https://doi.org/10.1201/9781315381572

Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease. / Lista, Simone; Zetterberg, Henrik; O'Bryant, Sidney; Blennow, Kaj; Hampel, Harald.

Dementia, Fifth Edition. CRC Press, 2017. p. 528-538.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease

AU - Lista, Simone

AU - Zetterberg, Henrik

AU - O'Bryant, Sidney

AU - Blennow, Kaj

AU - Hampel, Harald

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions (Hampel et al., 2010b; Hampel and Lista, 2013), which are detailed in Table 51.1.

AB - In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions (Hampel et al., 2010b; Hampel and Lista, 2013), which are detailed in Table 51.1.

UR - http://www.scopus.com/inward/record.url?scp=85053973026&partnerID=8YFLogxK

U2 - 10.1201/9781315381572

DO - 10.1201/9781315381572

M3 - Chapter

AN - SCOPUS:85053973026

SN - 9781498703123

SP - 528

EP - 538

BT - Dementia, Fifth Edition

PB - CRC Press

ER -

Lista S, Zetterberg H, O'Bryant S, Blennow K, Hampel H. Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease. In Dementia, Fifth Edition. CRC Press. 2017. p. 528-538 https://doi.org/10.1201/9781315381572